Leuzzi V, Carducci C, Carducci C, Chiarotti F, Artiola C, Giovanniello T, Antonozzi I
Department of Child Neurology and Psychiatry, University of Rome La Sapienza, Via dei Sabelli 108, 00185 Roma, Rome, Italy.
J Inherit Metab Dis. 2006 Feb;29(1):38-46. doi: 10.1007/s10545-006-0096-3.
A fall in blood phenylalanine (Phe) after tetrahydrobiopterin (BH(4)) administration is a common trait in phenylalanine hydroxylase (PAH, EC 1.14.16.1) deficiency (McKusick 261600). To explore the extent and biological correlates of this phenomenon we studied: (a) the spectrum of BH(4) response in patients with PAH deficiency; (b) the variability of BH(4) response according to the severity of the biochemical phenotype; and (c) the variability of the response to BH(4) in subjects with the same genotype. Fifty PAH-deficient subjects (age 1 month-35 years) were enrolled for the study (5 with mild hyperphenylalaninaemia (MHPHE), 15 with mild phenylketonuria (MPKU) and 30 with classic phenylketonuria (CPKU) and underwent an identical schedule of blood samplings 24 h before and after oral BH(4) challenge (6(R)-BH4, 20 mg/kg per day), leaving Phe intake unchanged. The effect of BH(4) on blood Phe concentration was evaluated according to the percent decrease of Phe during the 24 h following the challenge (criterion a), and as variation exceeding the individual variability of blood Phe (criterion b). The number of BH(4)-responders according to criterion b was 31 (including all the 14 detected by criterion a): 17 out of 30 CPKU (57%), 9 out of 15 MPKU (60%), and all the MHPHE subjects (chi(2) = 3.45, df = 2, p = 0.178). The effect of BH(4) showed a large interindividual variability unrelated to diagnostic classification, basal value of blood Phe, maximum percentage of Phe reduction, Phe intake, and genotype. Some inconsistencies were found in patients with identical genotype. The first responsive case homozygous for the severe R408W mutation was found. Two new mutations, Y387X and G352C, were identified (the former was BH(4)-responsive), and the responsiveness of three already reported mutations (R261Q, D338Y, T92I) was substantiated.
给予四氢生物蝶呤(BH(4))后血苯丙氨酸(Phe)水平下降是苯丙氨酸羟化酶(PAH,EC 1.14.16.1)缺乏症(麦库西克编号261600)的常见特征。为探究这一现象的程度及其生物学关联,我们进行了以下研究:(a)PAH缺乏症患者的BH(4)反应谱;(b)根据生化表型严重程度的BH(4)反应变异性;(c)相同基因型受试者对BH(4)反应的变异性。五十名PAH缺乏症受试者(年龄1个月至35岁)纳入本研究(5例轻度高苯丙氨酸血症(MHPHE)、15例轻度苯丙酮尿症(MPKU)和30例经典苯丙酮尿症(CPKU)),在口服BH(4)激发试验(6(R)-BH4,每天20mg/kg)前后24小时接受相同的采血计划,同时保持Phe摄入量不变。根据激发试验后24小时内Phe的下降百分比(标准a)以及超过血Phe个体变异性的变化(标准b)来评估BH(4)对血Phe浓度的影响。根据标准b,BH(4)反应者有31例(包括标准a检测出的所有14例):30例CPKU中有17例(57%),15例MPKU中有9例(60%),以及所有MHPHE受试者(卡方检验:χ(2)=3.45,自由度df = 2,p = 0.178)。BH(4)的作用表现出较大的个体间变异性,与诊断分类、血Phe基础值、Phe最大降低百分比、Phe摄入量及基因型无关。在相同基因型的患者中发现了一些不一致情况。发现了第一例对严重R408W突变纯合的反应性病例。鉴定出两个新突变Y387X和G352C(前者对BH(4)有反应),并证实了三个已报道突变(R261Q、D338Y、T92I)的反应性。